Skip to main content
Top
Published in: BMC Public Health 1/2013

Open Access 01-12-2013 | Research article

Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis

Authors: Heidemarie Keller, Oliver Hirsch, Petra Kaufmann-Kolle, Tanja Krones, Annette Becker, Andreas C Sönnichsen, Erika Baum, Norbert Donner-Banzhoff

Published in: BMC Public Health | Issue 1/2013

Login to get access

Abstract

Background

The prescription of statins is an evidence-based treatment to reduce the risk of cardiovascular events in patients with elevated cardiovascular risk or with a cardiovascular disorder (CVD). In spite of this, many of these patients do not receive statins.

Methods

We evaluated the impact of a brief educational intervention in cardiovascular prevention in primary care physicians’ prescribing behaviour regarding statins beyond their participation in a randomised controlled trial (RCT). For this, prescribing data of all patients > 35 years who were counselled before and after the study period were analysed (each n > 75000). Outcome measure was prescription of Hydroxymethylglutaryl-CoA Reductase Inhibitors (statins) corresponding to patients’ overall risk for CVD. Appropriateness of prescribing was examined according to different risk groups based on the Anatomical Therapeutic Chemical Classification System (ATC codes).

Results

There was no consistent association between group allocation and statin prescription controlling for risk status in each risk group before and after study participation. However, we found a change to more significant drug configurations predicting the prescription of statins in the intervention group, which can be regarded as a small intervention effect.

Conclusion

Our results suggest that an active implementation of a brief evidence-based educational intervention does not lead to prescription modifications in everyday practice. Physician’s prescribing behaviour is affected by an established health care system, which is not easy to change.

Trial registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007, 14 (Suppl 2): S1-S113.CrossRefPubMed Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007, 14 (Suppl 2): S1-S113.CrossRefPubMed
2.
go back to reference Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM: Long-term follow-up of the west of scotland coronary prevention study. N Engl J Med. 2007, 357 (15): 1477-1486. 10.1056/NEJMoa065994.CrossRefPubMed Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM: Long-term follow-up of the west of scotland coronary prevention study. N Engl J Med. 2007, 357 (15): 1477-1486. 10.1056/NEJMoa065994.CrossRefPubMed
3.
go back to reference Gotto AM: Establishing the benefit of statins in low-to-moderate–risk primary prevention: the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Atheroscler Suppl. 2007, 8 (2): 3-8. 10.1016/j.atherosclerosissup.2007.02.002.CrossRefPubMed Gotto AM: Establishing the benefit of statins in low-to-moderate–risk primary prevention: the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Atheroscler Suppl. 2007, 8 (2): 3-8. 10.1016/j.atherosclerosissup.2007.02.002.CrossRefPubMed
4.
go back to reference Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group. N Engl J Med. 1995, 333 (20): 1301-1307. 10.1056/NEJM199511163332001.CrossRefPubMed Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group. N Engl J Med. 1995, 333 (20): 1301-1307. 10.1056/NEJM199511163332001.CrossRefPubMed
5.
go back to reference van de Steeg-van Gompel CH, Wensing M, De Smet PA: Implementation of a pharmacist-led intervention to enhance statin prescribing for secondary prevention in primary care: a cluster randomized trial. Eur J Prev Cardiol. 2012, 19 (2): 169-176. 10.1177/1741826711398846.CrossRefPubMed van de Steeg-van Gompel CH, Wensing M, De Smet PA: Implementation of a pharmacist-led intervention to enhance statin prescribing for secondary prevention in primary care: a cluster randomized trial. Eur J Prev Cardiol. 2012, 19 (2): 169-176. 10.1177/1741826711398846.CrossRefPubMed
6.
go back to reference Bennett KE, Williams D, Feely J: Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol. 2003, 58 (12): 835-841.PubMed Bennett KE, Williams D, Feely J: Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol. 2003, 58 (12): 835-841.PubMed
7.
go back to reference Harder S, Fischer P, Krause-Schafer M, Ostermann K, Helms G, Prinz H, Hahmann M, Baas H: Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol. 2005, 60 (11): 797-805. 10.1007/s00228-004-0838-9.CrossRefPubMed Harder S, Fischer P, Krause-Schafer M, Ostermann K, Helms G, Prinz H, Hahmann M, Baas H: Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol. 2005, 60 (11): 797-805. 10.1007/s00228-004-0838-9.CrossRefPubMed
8.
go back to reference Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njolstad I: Whom are we treating with lipid-lowering drugs? Are we following the guidelines? evidence from a population-based study: the tromso study 2001. Eur J Clin Pharmacol. 2004, 60 (9): 643-649. 10.1007/s00228-004-0827-z.CrossRefPubMed Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njolstad I: Whom are we treating with lipid-lowering drugs? Are we following the guidelines? evidence from a population-based study: the tromso study 2001. Eur J Clin Pharmacol. 2004, 60 (9): 643-649. 10.1007/s00228-004-0827-z.CrossRefPubMed
9.
go back to reference Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP: Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009, 8: 25-10.1186/1475-2840-8-25.CrossRefPubMedPubMedCentral Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP: Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009, 8: 25-10.1186/1475-2840-8-25.CrossRefPubMedPubMedCentral
10.
go back to reference Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A, Degli Esposti E: Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol. 2005, 61 (3): 225-230. 10.1007/s00228-005-0911-z.CrossRefPubMed Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A, Degli Esposti E: Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol. 2005, 61 (3): 225-230. 10.1007/s00228-005-0911-z.CrossRefPubMed
11.
go back to reference Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N: Adherence to statin therapy and patients’ cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol. 2008, 64 (4): 425-432. 10.1007/s00228-007-0428-8.CrossRefPubMed Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N: Adherence to statin therapy and patients’ cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol. 2008, 64 (4): 425-432. 10.1007/s00228-007-0428-8.CrossRefPubMed
12.
go back to reference JBS: JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005, 91: v1-v52.CrossRef JBS: JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005, 91: v1-v52.CrossRef
13.
go back to reference De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003, 24 (17): 1601-1610. 10.1016/S0195-668X(03)00347-6.CrossRefPubMed De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003, 24 (17): 1601-1610. 10.1016/S0195-668X(03)00347-6.CrossRefPubMed
14.
go back to reference Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, et al: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006, 114 (1): 82-96. 10.1161/CIRCULATIONAHA.106.176158.CrossRefPubMed Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, et al: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006, 114 (1): 82-96. 10.1161/CIRCULATIONAHA.106.176158.CrossRefPubMed
15.
go back to reference Sheridan S, Pignone M, Mulrow C: Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med. 2003, 18 (12): 1039-1052. 10.1111/j.1525-1497.2003.30107.x.CrossRefPubMedPubMedCentral Sheridan S, Pignone M, Mulrow C: Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med. 2003, 18 (12): 1039-1052. 10.1111/j.1525-1497.2003.30107.x.CrossRefPubMedPubMedCentral
16.
go back to reference Krones T, Keller H, Sonnichsen A, Sadowski EM, Baum E, Wegscheider K, Rochon J, Donner-Banzhoff N: Absolute cardiovascular disease risk and shared decision making in primary care: A randomized controlled trial. Ann Fam Med. 2008, 6 (3): 218-227. 10.1370/afm.854.CrossRefPubMedPubMedCentral Krones T, Keller H, Sonnichsen A, Sadowski EM, Baum E, Wegscheider K, Rochon J, Donner-Banzhoff N: Absolute cardiovascular disease risk and shared decision making in primary care: A randomized controlled trial. Ann Fam Med. 2008, 6 (3): 218-227. 10.1370/afm.854.CrossRefPubMedPubMedCentral
17.
go back to reference O‘Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, et al: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009, 3: CD001431-PubMed O‘Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, et al: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009, 3: CD001431-PubMed
18.
go back to reference Wensing M, Broge B, Kaufmann-Kolle P, Andres E, Szecsenyi J: Quality circles to improve prescribing patterns in primary medical care: what is their actual impact?. J Eval Clin Pract. 2004, 10 (3): 457-466. 10.1111/j.1365-2753.2004.00517.x.CrossRefPubMed Wensing M, Broge B, Kaufmann-Kolle P, Andres E, Szecsenyi J: Quality circles to improve prescribing patterns in primary medical care: what is their actual impact?. J Eval Clin Pract. 2004, 10 (3): 457-466. 10.1111/j.1365-2753.2004.00517.x.CrossRefPubMed
19.
go back to reference Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, Tyrer P: Framework for design and evaluation of complex interventions to improve health. BMJ. 2000, 321 (7262): 694-696. 10.1136/bmj.321.7262.694.CrossRefPubMedPubMedCentral Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, Tyrer P: Framework for design and evaluation of complex interventions to improve health. BMJ. 2000, 321 (7262): 694-696. 10.1136/bmj.321.7262.694.CrossRefPubMedPubMedCentral
20.
go back to reference Hirsch O, Keller H, Albohn-Kuhne C, Krones T, Donner-Banzhoff N: Satisfaction of patients and primary care physicians with shared decision making. Eval Health Prof. 2010, 33 (3): 321-342. 10.1177/0163278710376662.CrossRefPubMed Hirsch O, Keller H, Albohn-Kuhne C, Krones T, Donner-Banzhoff N: Satisfaction of patients and primary care physicians with shared decision making. Eval Health Prof. 2010, 33 (3): 321-342. 10.1177/0163278710376662.CrossRefPubMed
21.
go back to reference Keller H, Krones T, Becker A, Hirsch O, Sonnichsen AC, Popert U, Kaufmann-Kolle P, Rochon J, Wegscheider K, Baum E, et al: Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. Eur J Prev Cardiol. 2012, 19 (3): 322-329. 10.1177/1741826711404502.CrossRefPubMed Keller H, Krones T, Becker A, Hirsch O, Sonnichsen AC, Popert U, Kaufmann-Kolle P, Rochon J, Wegscheider K, Baum E, et al: Arriba: effects of an educational intervention on prescribing behaviour in prevention of CVD in general practice. Eur J Prev Cardiol. 2012, 19 (3): 322-329. 10.1177/1741826711404502.CrossRefPubMed
22.
go back to reference Martirosyan L, Arah OA, Haaijer-Ruskamp FM, Braspenning J, Denig P: Methods to identify the target population: implications for prescribing quality indicators. BMC Health Serv Res. 2010, 10: 137-10.1186/1472-6963-10-137.CrossRefPubMedPubMedCentral Martirosyan L, Arah OA, Haaijer-Ruskamp FM, Braspenning J, Denig P: Methods to identify the target population: implications for prescribing quality indicators. BMC Health Serv Res. 2010, 10: 137-10.1186/1472-6963-10-137.CrossRefPubMedPubMedCentral
23.
go back to reference Landau S, Everitt BS: A handbook of statistical analyses using SPSS. 2004, Boca Raton: Chapman & Hall Landau S, Everitt BS: A handbook of statistical analyses using SPSS. 2004, Boca Raton: Chapman & Hall
24.
go back to reference World Health Organisation: Guidelines for ATC classification and DDD assignment. 2010, Oslo: WHO Collaborating Centre for Drug Statistics Methodology World Health Organisation: Guidelines for ATC classification and DDD assignment. 2010, Oslo: WHO Collaborating Centre for Drug Statistics Methodology
25.
go back to reference Grissom RJ, Kim JJ: Effect sizes for research.A broad practical approach. 2005, Mahwah: Lawrence Erlbaum Associates Grissom RJ, Kim JJ: Effect sizes for research.A broad practical approach. 2005, Mahwah: Lawrence Erlbaum Associates
26.
go back to reference Ellis PD: The essential guide to effect sizes. Statistical power, meta-analysis, and the interpretation of research results. 2010, Cambridge: Cambridge University PressCrossRef Ellis PD: The essential guide to effect sizes. Statistical power, meta-analysis, and the interpretation of research results. 2010, Cambridge: Cambridge University PressCrossRef
27.
go back to reference Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat. 1979, 6: 65-70. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat. 1979, 6: 65-70.
28.
go back to reference von Eye A: Configural frequency analysis: Methods, models and applications. 2002, Hillsdale: Lawrence Erlbaum Associates von Eye A: Configural frequency analysis: Methods, models and applications. 2002, Hillsdale: Lawrence Erlbaum Associates
29.
go back to reference Krauth J: Einführung in die Konfigurationsfrequenzanalyse (KFA) [Introduction to configural frequency analysis]. 1993, Beltz: Weinheim Krauth J: Einführung in die Konfigurationsfrequenzanalyse (KFA) [Introduction to configural frequency analysis]. 1993, Beltz: Weinheim
30.
go back to reference Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM: Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Arch Intern Med. 2010, 170 (5): 470-477. 10.1001/archinternmed.2009.525.CrossRefPubMed Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM: Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Arch Intern Med. 2010, 170 (5): 470-477. 10.1001/archinternmed.2009.525.CrossRefPubMed
31.
go back to reference Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM: Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007, 32 (5): 403-407. 10.1016/j.amepre.2007.01.010.CrossRefPubMed Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM: Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007, 32 (5): 403-407. 10.1016/j.amepre.2007.01.010.CrossRefPubMed
32.
go back to reference Stafford RS, Monti V, Ma J: Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005, 2 (12): e353-10.1371/journal.pmed.0020353.CrossRefPubMedPubMedCentral Stafford RS, Monti V, Ma J: Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005, 2 (12): e353-10.1371/journal.pmed.0020353.CrossRefPubMedPubMedCentral
33.
go back to reference Manes C, Giacci L, Sciartilli A, D‘Alleva A, De Caterina R: Aspirin overprescription in primary cardiovascular prevention. Thromb Res. 2006, 118 (4): 471-477. 10.1016/j.thromres.2005.09.013.CrossRefPubMed Manes C, Giacci L, Sciartilli A, D‘Alleva A, De Caterina R: Aspirin overprescription in primary cardiovascular prevention. Thromb Res. 2006, 118 (4): 471-477. 10.1016/j.thromres.2005.09.013.CrossRefPubMed
34.
go back to reference Bradley CP: Decision making and prescribing patterns–a literature review. Fam Pract. 1991, 8 (3): 276-287. 10.1093/fampra/8.3.276.CrossRefPubMed Bradley CP: Decision making and prescribing patterns–a literature review. Fam Pract. 1991, 8 (3): 276-287. 10.1093/fampra/8.3.276.CrossRefPubMed
35.
go back to reference Jones MI, Greenfield SM, Bradley CP: Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001, 323 (7309): 378-381. 10.1136/bmj.323.7309.378.CrossRefPubMedPubMedCentral Jones MI, Greenfield SM, Bradley CP: Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001, 323 (7309): 378-381. 10.1136/bmj.323.7309.378.CrossRefPubMedPubMedCentral
36.
go back to reference Grol R: Changing physicians’ competence and performance: finding the balance between the individual and the organization. J Contin Educ Health Prof. 2002, 22 (4): 244-251. 10.1002/chp.1340220409.CrossRefPubMed Grol R: Changing physicians’ competence and performance: finding the balance between the individual and the organization. J Contin Educ Health Prof. 2002, 22 (4): 244-251. 10.1002/chp.1340220409.CrossRefPubMed
37.
go back to reference Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003, 362 (9391): 1225-1230. 10.1016/S0140-6736(03)14546-1.CrossRefPubMed Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003, 362 (9391): 1225-1230. 10.1016/S0140-6736(03)14546-1.CrossRefPubMed
38.
go back to reference Durack-Bown I, Giral P, d‘Ivernois JF, Bazin C, Chadarevian R, Benkritly A, Bruckert E: Patients’ and physicians’ perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract. 2003, 53 (496): 851-857.PubMedPubMedCentral Durack-Bown I, Giral P, d‘Ivernois JF, Bazin C, Chadarevian R, Benkritly A, Bruckert E: Patients’ and physicians’ perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract. 2003, 53 (496): 851-857.PubMedPubMedCentral
39.
go back to reference Ali NS: Prediction of coronary heart disease preventive behaviors in women: a test of the health belief model. Women Health. 2002, 35 (1): 83-96. 10.1300/J013v35n01_06.CrossRefPubMed Ali NS: Prediction of coronary heart disease preventive behaviors in women: a test of the health belief model. Women Health. 2002, 35 (1): 83-96. 10.1300/J013v35n01_06.CrossRefPubMed
40.
go back to reference Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, Ahern DK: Patients’ perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med. 2006, 4 (3): 205-212. 10.1370/afm.534.CrossRefPubMedPubMedCentral Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, Ahern DK: Patients’ perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med. 2006, 4 (3): 205-212. 10.1370/afm.534.CrossRefPubMedPubMedCentral
41.
go back to reference Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M: When is it cost-effective to change the behavior of health professionals?. JAMA. 2001, 286 (23): 2988-2992. 10.1001/jama.286.23.2988.CrossRefPubMed Mason J, Freemantle N, Nazareth I, Eccles M, Haines A, Drummond M: When is it cost-effective to change the behavior of health professionals?. JAMA. 2001, 286 (23): 2988-2992. 10.1001/jama.286.23.2988.CrossRefPubMed
42.
go back to reference Vandenbroucke JP: Observational research, randomised trials, and two views of medical science. PLoS Med. 2008, 5 (3): e67-10.1371/journal.pmed.0050067.CrossRefPubMedPubMedCentral Vandenbroucke JP: Observational research, randomised trials, and two views of medical science. PLoS Med. 2008, 5 (3): e67-10.1371/journal.pmed.0050067.CrossRefPubMedPubMedCentral
43.
go back to reference Chini F, Pezzotti P, Orzella L, Borgia P, Guasticchi G: Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources. BMC Publ Health. 2011, 11: 688-10.1186/1471-2458-11-688.CrossRef Chini F, Pezzotti P, Orzella L, Borgia P, Guasticchi G: Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources. BMC Publ Health. 2011, 11: 688-10.1186/1471-2458-11-688.CrossRef
Metadata
Title
Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis
Authors
Heidemarie Keller
Oliver Hirsch
Petra Kaufmann-Kolle
Tanja Krones
Annette Becker
Andreas C Sönnichsen
Erika Baum
Norbert Donner-Banzhoff
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2013
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-13-623

Other articles of this Issue 1/2013

BMC Public Health 1/2013 Go to the issue